Jun. 4 at 11:06 PM
$VSTM Verastem Oncology entered into a collaboration agreement with GenFleet Therapeutics for three discovery programs, with exclusive options to license three compounds upon successful completion of predetermined Phase 1 milestones. These licenses would grant Verastem development and commercialization rights outside of GenFleet territories (mainland China, Hong Kong, Macau, and Taiwan).
VS-7375 (known as GFH375 in China), a potential best-in-class, potent and selective oral KRAS G12D (ON/OFF) inhibitor, has been identified as the lead discovery program. GenFleet’s IND for GFH375 (VS-7375) was approved in June 2024, and they are currently conducting Phase 1/2 and Phase 3 clinical trials in China.
